Blog
RSS FeedPosted by Michael Wonder on 24 Jan 2020
Ready for rescue – new nasally administered glucagon for severe hypoglycaemia available in Canada
23 January 2020 - Eli Lilly Canada introduces Baqsimi, another Canadian innovation to help manage diabetes complications. ...
Posted by Michael Wonder on 24 Jan 2020
HLS Therapeutics files new drug submission for Perseris in Canada
23 January 2020 - If approved by Health Canada, Perseris would become the first once-monthly risperidone long-acting injectable used in the ...
Posted by Michael Wonder on 24 Jan 2020
Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with advanced renal cell carcinoma
23 January 2020 - Approval based on results of KEYNOTE-426, Where Keytruda in combination with axitinib reduced the risk of death ...
Posted by Michael Wonder on 22 Jan 2020
Morneau says Ottawa will need to work with provinces on issues like universal pharmacare
19 January 2020 - Finance Minister Bill Morneau said that the federal government will often need to work together with provinces ...
Posted by Michael Wonder on 22 Jan 2020
Amazon just filed a bunch of international trademarks for ‘Amazon Pharmacy’
21 January 2020 - Amazon bought an Internet pharmacy business called PillPack in 2018. ...
Posted by Michael Wonder on 19 Jan 2020
Is innovation causing accessibility, timing issues for private drug plans?
17 January 2020 - Pharmaceutical companies and private payers can interact in different ways to ensure the right drugs are ...
Posted by Michael Wonder on 16 Jan 2020
Why Canada won't end up as the drugstore to the U.S.
16 January 2020 - Although in theory the new U.S. import proposals could significantly affect Canadians and their drug supplies, their ...
Posted by Michael Wonder on 16 Jan 2020
Cimzia (certolizumab pegol) now approved in Canada for the treatment of non-radiographic axial spondyloarthritis
15 January 2020 - UCB Canada announced today that Health Canada has approved Cimzia (certolizumab pegol) for the treatment of adults ...
Posted by Michael Wonder on 15 Jan 2020
Health Canada approves Astellas' Xospata (gilteritinib) for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
14 January 2020 - Xospata is the first and only targeted treatment approved by Health Canada for patients with relapsed or ...
Posted by Michael Wonder on 14 Jan 2020
B.C. funding decision on pricey drug leaves teen with rare disease facing 'scary' future
13 January 2020 - Miles Ambridge just misses cut-off age to access Spinraza, a potentially life-changing treatment. ...
Posted by Michael Wonder on 14 Jan 2020
Health insurance industry pooling mechanism makes high cost drugs accessible for record number of Canadians
14 January 2020 - The catastrophic expense of high cost drugs have been made affordable for a record number of ...
Posted by Michael Wonder on 09 Jan 2020
Alignment of terminology
9 January 2020 - CADTH is aligning the terminology in the single drug review processes as follows: ...
Posted by Michael Wonder on 09 Jan 2020
New CADTH process for cell and gene therapies
9 January 2020 - CADTH has undertaken an internal review of our processes for drugs and devices, and established a revised ...
Posted by Michael Wonder on 09 Jan 2020
U.S. health care system costs four times more to run than Canada’s single payer system
7 January 2020 - In the United States, a legion of administrative health care workers and health insurance employees who ...
Posted by Michael Wonder on 09 Jan 2020
New treatment approved in Canada for most common type of leukaemia
8 January 2020 - Calquence (acalabrutinib) is now available for adult patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. ...